Experienced Congressional Legislative Director Joins HB Strategies Federal Team

Meghan Schmidtlein, former Legislative Director to U.S. Representative Blaine Luetkemeyer, has joined the HB Strategies Federal team as a Principal in the firm’s Washington, DC office. She served on Capitol Hill for ten years as a legislative staff member to senior members of Congress and two years helping to lead federal advocacy for one of the nation’s largest and top-ranked state university systems.

HB Strategies Federal Team Releases Calendar for New Congress

Now is the time to prepare for next year as a new Congress is sworn in January 3, 2025. The HB Strategies Federal team in Washington has prepared a user-friendly reference calendar showing the House and Senate legislative schedules, State and District work periods, and federal holidays.

HB Strategies CEO Andy Blunt Takes a Closer Look at Election Night Returns

Ballots are still being counted across the United States but former President Donald Trump has secured enough electoral votes to return to the White House and HB Strategies CEO Andy Blunt  has spent the day after Election Day taking a closer look at the returns for the presidential race as well as Congress and state governors.

HB Strategies CEO Andy Blunt Anticipates Election Night Will Turn to Days

In today’s snapshot report, Political Overtime, Andy notes seven swing states are the key to what happens and “the outcome of the presidential election could take a week to sort out and if only a few votes in competitive districts is separating the candidates, then it could be close to a month after Election Day until we determine control of the House.”

HB Strategies Report Examines Private Equity Investment in Healthcare and its Government Risk

In the first of a new series of public policy and regulatory reports, the HB Strategies team assesses current risks from Congress and state legislatures to private equity investments in healthcare. The HB Strategies REPORT Private Equity Investment in Healthcare outlines obstacles impacting private equity and provides a proactive blueprint to safeguard innovative investments in healthcare.